Wolfram E Samlowski

Summary

Affiliation: University of Utah
Country: USA

Publications

  1. ncbi request reprint A nonpeptidyl mimic of superoxide dismutase, M40403, inhibits dose-limiting hypotension associated with interleukin-2 and increases its antitumor effects
    Wolfram E Samlowski
    Melanoma Program, Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope Drive, Salt Lake City, Utah 84112, USA
    Nat Med 9:750-5. 2003
  2. ncbi request reprint Evaluation of a 7-day continuous intravenous infusion of decitabine: inhibition of promoter-specific and global genomic DNA methylation
    Wolfram E Samlowski
    Huntsman Cancer Institute and the Department of Internal Medicine Oncology, University of Utah, Salt Lake City, UT 84112 5550, USA
    J Clin Oncol 23:3897-905. 2005
  3. ncbi request reprint ReGel polymer-based delivery of interleukin-2 as a cancer treatment
    Wolfram E Samlowski
    Multidisciplinary Melanoma Program, Huntsman Cancer Institute, 2000 Circle of Hope Drive, Salt Lake City, UT 84112, USA
    J Immunother 29:524-35. 2006
  4. ncbi request reprint Evaluation of the combination of docetaxel/carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN): a Southwest Oncology Group Phase II study
    Wolfram E Samlowski
    University of Utah Health Science Center, Salt Lake City, Utah, USA
    Cancer Invest 25:182-8. 2007
  5. ncbi request reprint Multimodality treatment of melanoma brain metastases incorporating stereotactic radiosurgery (SRS)
    Wolfram E Samlowski
    Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah 84112, USA
    Cancer 109:1855-62. 2007
  6. ncbi request reprint Biochemotherapy of metastatic melanoma in patients with or without recently diagnosed brain metastases
    Martin Majer
    Multidisciplinary Melanoma Program, Huntsman Cancer Institute, Salt Lake City, Utah, USA
    Cancer 110:1329-37. 2007
  7. doi request reprint Inducible nitric oxide synthase (iNOS) is not required for IL-2-induced hypotension and vascular leak syndrome in mice
    Muralidhar Kondapaneni
    Division of Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA
    J Immunother 31:325-33. 2008
  8. ncbi request reprint Population-based prevalence of CDKN2A mutations in Utah melanoma families
    Mark J Eliason
    Department of Dermatology, University of Utah Health Sciences Center, Salt Lake City, Utah, USA
    J Invest Dermatol 126:660-6. 2006
  9. ncbi request reprint Population-based analysis of prognostic factors and survival in familial melanoma
    Scott R Florell
    Department of Dermatology, Melanoma Program, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA
    J Clin Oncol 23:7168-77. 2005
  10. pmc N-acetylcysteine protects melanocytes against oxidative stress/damage and delays onset of ultraviolet-induced melanoma in mice
    Murray A Cotter
    Department of Dermatology, Huntsman Cancer Institute, Salt Lake City, Utah 84112, USA
    Clin Cancer Res 13:5952-8. 2007

Research Grants

  1. Phase I trial of PHP with high-dose IL-2
    Wolfram Samlowski; Fiscal Year: 2006

Detail Information

Publications30

  1. ncbi request reprint A nonpeptidyl mimic of superoxide dismutase, M40403, inhibits dose-limiting hypotension associated with interleukin-2 and increases its antitumor effects
    Wolfram E Samlowski
    Melanoma Program, Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope Drive, Salt Lake City, Utah 84112, USA
    Nat Med 9:750-5. 2003
    ..These results established that M40403 prevented IL-2 from causing dose-limiting hypotension, while enhancing its anticancer activity...
  2. ncbi request reprint Evaluation of a 7-day continuous intravenous infusion of decitabine: inhibition of promoter-specific and global genomic DNA methylation
    Wolfram E Samlowski
    Huntsman Cancer Institute and the Department of Internal Medicine Oncology, University of Utah, Salt Lake City, UT 84112 5550, USA
    J Clin Oncol 23:3897-905. 2005
    ..A clinical study was designed to examine the molecular effects and toxicity of a continuous 1-week intravenous infusion of decitabine in solid tumor patients...
  3. ncbi request reprint ReGel polymer-based delivery of interleukin-2 as a cancer treatment
    Wolfram E Samlowski
    Multidisciplinary Melanoma Program, Huntsman Cancer Institute, 2000 Circle of Hope Drive, Salt Lake City, UT 84112, USA
    J Immunother 29:524-35. 2006
    ..This polymer delivery system is likely to be broadly applicable for sustained delivery of other cytokines and peptides...
  4. ncbi request reprint Evaluation of the combination of docetaxel/carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN): a Southwest Oncology Group Phase II study
    Wolfram E Samlowski
    University of Utah Health Science Center, Salt Lake City, Utah, USA
    Cancer Invest 25:182-8. 2007
    ..8 months (95%CI, 3.1-4.8) Median overall survival was 7.4 months (95%CI, 6.2-8.9). The results of this study suggest this regimen is active for outpatient treatment of recurrent SCCHN patients with good performance status...
  5. ncbi request reprint Multimodality treatment of melanoma brain metastases incorporating stereotactic radiosurgery (SRS)
    Wolfram E Samlowski
    Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah 84112, USA
    Cancer 109:1855-62. 2007
    ..We performed a retrospective analysis of our institutional experience of multimodality treatment utilizing linear accelerator (Linac)-based stereotactic radiosurgery (SRS)...
  6. ncbi request reprint Biochemotherapy of metastatic melanoma in patients with or without recently diagnosed brain metastases
    Martin Majer
    Multidisciplinary Melanoma Program, Huntsman Cancer Institute, Salt Lake City, Utah, USA
    Cancer 110:1329-37. 2007
    ....
  7. doi request reprint Inducible nitric oxide synthase (iNOS) is not required for IL-2-induced hypotension and vascular leak syndrome in mice
    Muralidhar Kondapaneni
    Division of Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA
    J Immunother 31:325-33. 2008
    ..These results imply that other NOS isoforms, such as endothelial NOS, may play a major role in the development of IL-2-induced cardiovascular toxicity...
  8. ncbi request reprint Population-based prevalence of CDKN2A mutations in Utah melanoma families
    Mark J Eliason
    Department of Dermatology, University of Utah Health Sciences Center, Salt Lake City, Utah, USA
    J Invest Dermatol 126:660-6. 2006
    ..We observed a significantly elevated rate of pancreatic cancer in one of four families with a deleterious CDKN2A mutation...
  9. ncbi request reprint Population-based analysis of prognostic factors and survival in familial melanoma
    Scott R Florell
    Department of Dermatology, Melanoma Program, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA
    J Clin Oncol 23:7168-77. 2005
    ..We sought to determine whether melanomas that occur in a familial setting demonstrate different prognostic and survival statistics relative to sporadic melanoma...
  10. pmc N-acetylcysteine protects melanocytes against oxidative stress/damage and delays onset of ultraviolet-induced melanoma in mice
    Murray A Cotter
    Department of Dermatology, Huntsman Cancer Institute, Salt Lake City, Utah 84112, USA
    Clin Cancer Res 13:5952-8. 2007
    ..We evaluated whether the thiol antioxidant N-acetylcysteine (NAC) could protect melanocytes from UV-induced oxidative stress/damage in vitro and from UV-induced melanoma in vivo...
  11. ncbi request reprint Metastatic melanoma in pregnancy: risk of transplacental metastases in the infant
    April Alexander
    Department of Dermatology, University of Utah, 2000 Circle of Hope, Room 5242, Salt Lake City, UT 84112 5550, USA
    J Clin Oncol 21:2179-86. 2003
    ..Although metastases to the fetus via the placenta are rare, melanoma is the most common culprit. When it occurs, maternally derived melanoma metastasis in the infant is almost invariably fatal...
  12. ncbi request reprint Molecular classification of melanoma using real-time quantitative reverse transcriptase-polymerase chain reaction
    Tracey B Lewis
    Research and Development, ARUP Laboratories Inc, Salt Lake City, Utah, USA
    Cancer 104:1678-86. 2005
    ..Molecular methods are more sensitive in detecting occult lymph node metastases compared with standard histopathology and are reported to have utility in clinical diagnostics...
  13. ncbi request reprint Suppression of cytokine-inducible nitric oxide synthesis during intraperitoneal Meth A tumor growth
    Oh Deog Kwon
    University of Utah Cancer Immunotherapy Program, Department of Internal Medicine of the University of Utah School of Medicine, Salt Lake City, 84132, USA
    J Vet Med Sci 66:357-65. 2004
    ..Thus, depletion of essential co-factors necessary for iNOS function may contribute to depressed NO* responses during cancer progression...
  14. ncbi request reprint Longitudinal assessment of the nevus phenotype in a melanoma kindred
    Scott R Florell
    The Melanoma Program, Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope, Salt Lake City, UT 84112 5550, USA
    J Invest Dermatol 123:576-82. 2004
    ..Continued accumulation of nevi in mutation carriers supports a nevogenic role for this CDKN2A mutation. An intermediate nevus phenotype in non-carrier family members suggests the presence of additional modifier genes...
  15. doi request reprint Patterns of enlarged lymph nodes in patients with metastatic renal cell carcinoma
    David A Hadley
    Division of Urology, University of Utah, Huntsman Cancer Institute, Salt Lake City, UT 84112, USA
    Urol Oncol 29:751-5. 2011
    ..We reviewed the imaging studies of patients with known metastatic renal cell carcinoma (RCC) in order to more accurately assess where retroperitoneal lymphadenopathy occurs...
  16. ncbi request reprint Melanoma
    Alan N Houghton
    J Natl Compr Canc Netw 4:666-84. 2006
  17. ncbi request reprint A Phase II trial of vinorelbine tartrate in patients with disseminated malignant melanoma and one prior systemic therapy: a Southwest Oncology Group study
    Robert P Whitehead
    University of Texas Medical Branch, Galveston, Texas, USA
    Cancer 100:1699-704. 2004
    ..In the current study, the authors evaluated the antitumor effects and toxicity of vinorelbine therapy in patients who had failed one prior systemic therapy...
  18. ncbi request reprint Multimodality management of brain metastases in metastatic melanoma patients
    Wolfram E Samlowski
    Section of Melanoma, Renal Cancer and Immunotherapy, Nevada Cancer Institute, One Breakthrough Way, 10441 W Twain Ave, Las Vegas, NV 89135, USA
    Expert Rev Anticancer Ther 7:1699-705. 2007
    ..Current data suggest that aggressive treatment of patients with up to five brain melanoma brain metastases is capable of producing prolonged survival in many patients, including some long-term complete responses...
  19. ncbi request reprint A phase II study of high-dose 24 hour continuous infusion 5-FU and leucovorin and low-dose PALA for patients with advanced pancreatic adenocarcinoma: a Southwest Oncology Group Study
    Robert P Whitehead
    University of Texas Medical Branch, Galveston, TX, USA
    Invest New Drugs 22:335-41. 2004
    ..The purpose of this phase II multi-institutional study was to define the efficacy and toxicity of infusional 5-FU in combination with PALA and leucovorin in patients with advanced pancreatic cancer...
  20. ncbi request reprint Management of metastatic melanoma patients with brain metastases
    Martin Majer
    Section of Melanoma, Renal Cancer and Immunotherapy, Nevada Cancer Institute, One Breakthrough Way, 10441 W Twain Avenue, Las Vegas, NV 89135, USA
    Curr Oncol Rep 9:411-6. 2007
    ..Our results suggest that the outcome of patients with melanoma brain metastases can be improved using a multidisciplinary management strategy...
  21. ncbi request reprint Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma
    Malcolm S Mitchell
    University of California, San Diego, School of Medicine and Cancer Center, San Diego, CA, USA
    J Clin Oncol 25:2078-85. 2007
    ..To compare the overall survival (OS) of patients with resected stage III melanoma administered active specific immunotherapy and low-dose interferon alfa-2b (IFN-alpha-2b) with the OS achieved using high-dose IFN-alpha-2b...
  22. ncbi request reprint Reversible diplopia induced by high-dose intravenous IL-2 therapy
    Jayaram S Bharadwaj
    The University of Utah Cancer Immunotherapy Program, UT, USA
    Clin Adv Hematol Oncol 2:471; discussion 472. 2004
  23. doi request reprint Management of renal cancer in the tyrosine kinase inhibitor era: a view from 3 years on
    Wolfram E Samlowski
    Section of Melanoma, Renal Cancer and Immunotherapy, The Nevada Cancer Institute, Las Vegas, NV 89135, USA
    BJU Int 102:162-5. 2008
    ..This brief review is intended to overview recent developments, and to identify advances that are likely to influence treatment decisions...
  24. ncbi request reprint Kidney cancer. Clinical practice guidelines in oncology
    Robert J Motzer
    J Natl Compr Canc Netw 4:1072-81. 2006
  25. doi request reprint Increased melanocytic nevi and nevus density in a G-34T CDKN2A/p16 melanoma-prone pedigree
    Scott R Florell
    J Invest Dermatol 128:2122-5. 2008
  26. ncbi request reprint Phase 1 study of escalating-dose OncoGel (ReGel/paclitaxel) depot injection, a controlled-release formulation of paclitaxel, for local management of superficial solid tumor lesions
    Svetislava J Vukelja
    Tyler Cancer Center, Tyler, Texas, USA
    Anticancer Drugs 18:283-9. 2007
    ..Therefore, localized paclitaxel administration using OncoGel merits continued clinical development...
  27. ncbi request reprint Emerging drugs for the treatment of metastatic renal cancer
    Wolfram E Samlowski
    Section of Melanoma, Renal Cancer and Immunotherapy Nevada Cancer Institute, One Breakthrough Way, Las Vegas, NV 89135, USA
    Expert Opin Emerg Drugs 12:605-18. 2007
    ..These agents are rapidly progressing through clinical testing in renal cancer and in other malignancies. This paper overviews the status of these investigational agents and anticipates areas of future research and development...
  28. ncbi request reprint Nevus distribution in a Utah melanoma kindred with a temperature-sensitive CDKN2A mutation
    Scott R Florell
    J Invest Dermatol 125:1310-2. 2005
  29. ncbi request reprint Suppression of cytokine-inducible nitric oxide synthesis during intraperitoneal meth a tumor growth
    Oh Deog Kwon
    University of Utah Cancer Immunotherapy Program, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City 84132, USA
    J Vet Med Sci 66:357-65. 2004
    ..Thus, depletion of essential co-factors necessary for iNOS function may contribute to depressed NO* responses during cancer progression...
  30. ncbi request reprint Failure to detect differences in proliferation status of nevi from CDKN2A mutation carriers and non-carriers
    Scott R Florell
    J Invest Dermatol 118:386-7. 2002

Research Grants1

  1. Phase I trial of PHP with high-dose IL-2
    Wolfram Samlowski; Fiscal Year: 2006
    ..abstract_text> ..